Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.
(Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
Sponsor:
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00488670
First received: June 18, 2007
Last updated: June 2, 2011
Last verified: June 2011
  Purpose

To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.


Condition Intervention Phase
Depressive Disorder
Drug: Escitalopram
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Change in Cornell Scale for Depression in Dementia (CSDD) from baseline. [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: December 2010
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Escitalopram
    See Detailed Description.
Detailed Description:

This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00488670

Locations
Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada
Mt. St. Joseph's Hospital
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Investigators
Principal Investigator: Kiran Rabheru, MD University of British Columbia
  More Information

No publications provided

Responsible Party: Dr. Kiran Rabheru, University of British Columbia
ClinicalTrials.gov Identifier: NCT00488670     History of Changes
Other Study ID Numbers: H07-00050
Study First Received: June 18, 2007
Last Updated: June 2, 2011
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
Alzheimer's disease
elderly
open-label
escitalopram

Additional relevant MeSH terms:
Alzheimer Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Mood Disorders
Behavioral Symptoms
Dexetimide
Citalopram
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 14, 2014